Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
otlertuzumab + rituximab
- Development stage
- Discontinued
- Lead developer
- Aptevo Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that induces direct caspase-independent apoptosis of malignant B cells and triggers antibody-dependent cell-mediated cytotoxicity. Rituximab is a chimeric monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. The combination of otlertuzumab and rituximab has been investigated for the treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Clinical studies have shown that this combination can be well tolerated and induce responses in patients with relapsed disease[2][6][8].
- Other names
- otlertuzumab + rituximabTRU-016 + rituximab
02
Targets
Beyond the preview
Go deeper on otlertuzumab + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on otlertuzumab + rituximab.